KIN

Kindred Bio Announces Initiation of Pivotal Clinical Study for AtoKinâ„¢ in Dogs

[PR Newswire] – SAN FRANCISCO, Feb. 20, 2014 /PRNewswire/ — Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-0 moreView todays social media effects on KINView the latest stocks trending across Twitter. Click to view dashboardSee who Kindred is hiring […]

LifeSci Advisors Initiates Coverage of Kindred Biosciences, Inc.

[Marketwired] – LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Kindred Biosciences, Inc. … moreView todays social media effects on KINView the latest stocks trending across Twitter. Click to view dashboardSee who Kindred is hiring next, click here to view […]